176 related articles for article (PubMed ID: 21873360)
1. Recurrent life-threatening deep tissue hematomas after switching to generic enoxaparin: a report and perspective on the approval process for biological compounds.
Kaffenberger BH; Bekaii-Saab T
Clin Appl Thromb Hemost; 2012; 18(1):104-6. PubMed ID: 21873360
[TBL] [Abstract][Full Text] [Related]
2. The United States Food and Drugs Administration approves a generic enoxaparin.
Ofosu FA
Clin Appl Thromb Hemost; 2011 Feb; 17(1):5-8. PubMed ID: 21159709
[TBL] [Abstract][Full Text] [Related]
3. Structure and haemostatic effects of generic versions of enoxaparin available for clinical use in Brazil: similarity to the original drug.
Glauser BF; Vairo BC; Oliveira SN; Cinelli LP; Pereira MS; Mourão PA
Thromb Haemost; 2012 Feb; 107(2):302-14. PubMed ID: 22234635
[TBL] [Abstract][Full Text] [Related]
4. FDA approves generic enoxaparin.
Voelker R
JAMA; 2010 Aug; 304(8):844. PubMed ID: 20736461
[No Abstract] [Full Text] [Related]
5. Generic low-molecular-weight heparins: some practical considerations.
Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
[TBL] [Abstract][Full Text] [Related]
6. Overview on guidelines and recommendations for generic low-molecular-weight heparins.
Harenberg J
Thromb Res; 2011 Feb; 127 Suppl 3():S100-4. PubMed ID: 21262425
[TBL] [Abstract][Full Text] [Related]
7. An open label, non-randomized, prospective clinical trial evaluating the immunogenicity of branded enoxaparin versus biosimilars in healthy volunteers.
Gomes M; Ramacciotti E; Hoppensteadt D; Walenga JM; Lewis B; Thethi I; Fareed J
Clin Appl Thromb Hemost; 2011 Feb; 17(1):66-9. PubMed ID: 21220365
[TBL] [Abstract][Full Text] [Related]
8. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
[TBL] [Abstract][Full Text] [Related]
9. Active and passive surveillance of enoxaparin generics: a case study relevant to biosimilars.
Grampp G; Bonafede M; Felix T; Li E; Malecki M; Sprafka JM
Expert Opin Drug Saf; 2015 Mar; 14(3):349-60. PubMed ID: 25557261
[TBL] [Abstract][Full Text] [Related]
10. New and generic anticoagulants and biosimilars: safety considerations.
Kalodiki E; Fareed J
Clin Appl Thromb Hemost; 2011 Apr; 17(2):136-9. PubMed ID: 21159711
[TBL] [Abstract][Full Text] [Related]
11. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
Feng L; Shen-Tu J; Liu J; Chen J; Wu L; Huang M
Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
Stellbrink C; Nixdorff U; Hofmann T; Lehmacher W; Daniel WG; Hanrath P; Geller C; Mügge A; Sehnert W; Schmidt-Lucke C; Schmidt-Lucke JA;
Circulation; 2004 Mar; 109(8):997-1003. PubMed ID: 14967716
[TBL] [Abstract][Full Text] [Related]
13. FDA approves first generic enoxaparin product.
Thompson CA
Am J Health Syst Pharm; 2010 Sep; 67(18):1486, 1488. PubMed ID: 20811018
[No Abstract] [Full Text] [Related]
14. United States Food and Drug Administration requirements for approval of generic drug products.
Meyer MC
J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
[TBL] [Abstract][Full Text] [Related]
15. Interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery.
Van Thiel D; Kalodiki E; Wahi R; Litinas E; Haque W; Rao G
Clin Appl Thromb Hemost; 2009; 15(4):389-94. PubMed ID: 19608550
[TBL] [Abstract][Full Text] [Related]
16. Hematoma of rectus sheath following subcutaneous enoxaparin injection.
Firoozbakhsh S; Parsaei R; Jafarshad R
Acta Med Iran; 2013 May; 51(5):334-6. PubMed ID: 23737319
[TBL] [Abstract][Full Text] [Related]
17. Skin necrosis induced by generic enoxaparin.
Gucalp A; Parameswaran R; Lacouture M; Abou-Alfa G; Soff G
Am J Hematol; 2013 Apr; 88(4):339. PubMed ID: 23450519
[No Abstract] [Full Text] [Related]
18. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial.
Veiga F; Escribá A; Maluenda MP; López Rubio M; Margalet I; Lezana A; Gallego J; Ribera JM
Thromb Haemost; 2000 Oct; 84(4):559-64. PubMed ID: 11057850
[TBL] [Abstract][Full Text] [Related]
19. Scientific considerations in the review and approval of generic enoxaparin in the United States.
Lee S; Raw A; Yu L; Lionberger R; Ya N; Verthelyi D; Rosenberg A; Kozlowski S; Webber K; Woodcock J
Nat Biotechnol; 2013 Mar; 31(3):220-6. PubMed ID: 23471071
[TBL] [Abstract][Full Text] [Related]
20. Abdominal wall hematomas associated with low-molecular-weight heparins: an important complication in older adults.
Nourbakhsh E; Anvari R; Nugent K
J Am Geriatr Soc; 2011 Aug; 59(8):1543-5. PubMed ID: 21848819
[No Abstract] [Full Text] [Related]
[Next] [New Search]
